Literature DB >> 25086631

Unvalidated antibodies and misleading results.

David Rimm1, Kurt Schalper, Lajos Pusztai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25086631      PMCID： PMC4216678          DOI： 10.1007/s10549-014-3061-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  10 in total

1.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

2.  Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE).

Authors:  Eric W Deutsch; Catherine A Ball; Jules J Berman; G Steven Bova; Alvis Brazma; Roger E Bumgarner; David Campbell; Helen C Causton; Jeffrey H Christiansen; Fabrice Daian; Delphine Dauga; Duncan R Davidson; Gregory Gimenez; Young Ah Goo; Sean Grimmond; Thorsten Henrich; Bernhard G Herrmann; Michael H Johnson; Martin Korb; Jason C Mills; Asa J Oudes; Helen E Parkinson; Laura E Pascal; Nicolas Pollet; John Quackenbush; Mirana Ramialison; Martin Ringwald; David Salgado; Susanna-Assunta Sansone; Gavin Sherlock; Christian J Stoeckert; Jason Swedlow; Ronald C Taylor; Laura Walashek; Anthony Warford; David G Wilkinson; Yi Zhou; Leonard I Zon; Alvin Y Liu; Lawrence D True
Journal:  Nat Biotechnol       Date:  2008-03       Impact factor: 54.908

Review 3.  Reproducibility of research and preclinical validation: problems and solutions.

Authors:  Lajos Pusztai; Christos Hatzis; Fabrice Andre
Journal:  Nat Rev Clin Oncol       Date:  2013-10-01       Impact factor: 66.675

Review 4.  Antibody validation.

Authors:  Jennifer Bordeaux; Allison Welsh; Seema Agarwal; Elizabeth Killiam; Maria Baquero; Jason Hanna; Valsamo Anagnostou; David Rimm
Journal:  Biotechniques       Date:  2010-03       Impact factor: 1.993

5.  PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

Authors:  Evan J Lipson; Jeremy G Vincent; Myriam Loyo; Luciane T Kagohara; Brandon S Luber; Hao Wang; Haiying Xu; Suresh K Nayar; Timothy S Wang; David Sidransky; Robert A Anders; Suzanne L Topalian; Janis M Taube
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

6.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

7.  Analytic variability in immunohistochemistry biomarker studies.

Authors:  Valsamo K Anagnostou; Allison W Welsh; Jennifer M Giltnane; Summar Siddiqui; Camil Liceaga; Mark Gustavson; Konstantinos N Syrigos; Jill L Reiter; David L Rimm
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

8.  Programmed death ligand-1 expression in non-small cell lung cancer.

Authors:  Vamsidhar Velcheti; Kurt A Schalper; Daniel E Carvajal; Valsamo K Anagnostou; Konstantinos N Syrigos; Mario Sznol; Roy S Herbst; Scott N Gettinger; Lieping Chen; David L Rimm
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

9.  Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

Authors:  Raoul A Droeser; Christian Hirt; Carsten T Viehl; Daniel M Frey; Christian Nebiker; Xaver Huber; Inti Zlobec; Serenella Eppenberger-Castori; Alexander Tzankov; Raffaele Rosso; Markus Zuber; Manuele Giuseppe Muraro; Francesca Amicarella; Eleonora Cremonesi; Michael Heberer; Giandomenica Iezzi; Alessandro Lugli; Luigi Terracciano; Giuseppe Sconocchia; Daniel Oertli; Giulio C Spagnoli; Luigi Tornillo
Journal:  Eur J Cancer       Date:  2013-03-13       Impact factor: 9.162

10.  In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

Authors:  Kurt A Schalper; Vamsidhar Velcheti; Daniel Carvajal; Hallie Wimberly; Jason Brown; Lajos Pusztai; David L Rimm
Journal:  Clin Cancer Res       Date:  2014-03-19       Impact factor: 12.531
  10 in total
  19 in total

1.  PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.

Authors:  François Bertucci; Pascal Finetti; Delphine Perrot; Agnès Leroux; Françoise Collin; Axel Le Cesne; Jean-Michel Coindre; Jean-Yves Blay; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2017-02-08       Impact factor: 8.110

2.  PDL1 expression is an independent prognostic factor in localized GIST.

Authors:  François Bertucci; Pascal Finetti; Emilie Mamessier; Maria Abbondanza Pantaleo; Annalisa Astolfi; Jerzy Ostrowski; Daniel Birnbaum
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.

Authors:  Emilien Billon; Pascal Finetti; Alexandre Bertucci; Patricia Niccoli; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Oncoimmunology       Date:  2019-08-28       Impact factor: 8.110

Review 4.  Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.

Authors:  François Bertucci; Anthony Gonçalves
Journal:  Curr Oncol Rep       Date:  2017-08-10       Impact factor: 5.075

5.  Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.

Authors:  Qian-Kun Xie; Yu-Jie Zhao; Tao Pan; Ning Lyu; Lu-Wen Mu; Shao-Long Li; Mu-De Shi; Zhen-Feng Zhang; Peng-Hui Zhou; Ming Zhao
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

6.  Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.

Authors:  Jing He; Lei Huo; Junsheng Ma; Jun Zhao; Roland L Bassett; Xiaoping Sun; Naoto T Ueno; Bora Lim; Yun Gong
Journal:  Am J Clin Pathol       Date:  2018-02-17       Impact factor: 2.493

7.  Prognostic and predictive value of PDL1 expression in breast cancer.

Authors:  Renaud Sabatier; Pascal Finetti; Emilie Mamessier; José Adelaide; Max Chaffanet; Hamid Raza Ali; Patrice Viens; Carlos Caldas; Daniel Birnbaum; François Bertucci
Journal:  Oncotarget       Date:  2015-03-10

8.  PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Authors:  François Bertucci; Pascal Finetti; Cécile Colpaert; Emilie Mamessier; Maxime Parizel; Luc Dirix; Patrice Viens; Daniel Birnbaum; Steven van Laere
Journal:  Oncotarget       Date:  2015-05-30

9.  Prognostic value of PDL1 expression in pancreatic cancer.

Authors:  David J Birnbaum; Pascal Finetti; Alexia Lopresti; Marine Gilabert; Flora Poizat; Olivier Turrini; Jean-Luc Raoul; Jean-Robert Delpero; Vincent Moutardier; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Oncotarget       Date:  2016-11-01

10.  Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.

Authors:  Woo Young Sun; Yu Kyung Lee; Ja Seung Koo
Journal:  J Transl Med       Date:  2016-06-10       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.